Immunotherapy Advances in Small Cell Lung Cancer
Immunotherapy Advances in Small Cell Lung Cancer
About this item
Full title
Author / Creator
XU, Yangyang , ZHAN, Ping and SONG, Yong
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Journal title
Language
Chinese
Formats
Publication information
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Subjects
More information
Scope and Contents
Contents
小细胞肺癌（small cell lung cancer, SCLC）是一种“顽固性癌症”，以快速生长和早期广泛转移为特征，大约70%的患者在确诊时就已经处于广泛期。尽管对一线含铂双联化疗反应率高，但是几乎所有患者随后即不可避免地复发且对二线治疗的反应较差。由于SCLC具有高肿瘤突变负荷及免疫源性，这提示免疫治疗也许对其有效。在过去的几年中，一些临床试验评估了以细胞毒性T淋巴细胞相关抗原4（cytotoxic T lymphocyte-associated antigen-4, CTLA-4）和程序性死亡受体1（programmed death 1, PD-1）/程序性死亡配体-1（programmed death ligand-1, PD-L1）抑制剂为主的检查点抑制剂在SCLC患者中的治...
Alternative Titles
Full title
Immunotherapy Advances in Small Cell Lung Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_af18e0f7dd444958b2a2210e6999830f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_af18e0f7dd444958b2a2210e6999830f
Other Identifiers
ISSN
1009-3419
E-ISSN
1999-6187
DOI
10.3779/j.issn.1009-3419.2020.105.02
